Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Geyer

Showing results (31-40 of 112) with videos related to

Pageof 12
Sort By:
Diabetes Care|July 14, 2018
A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at RiskMaria J Redondo, Susan Geyer, Andrea K Steck, et al.
JCI Insight|August 10, 2018
β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosisCarmella Evans-Molina, Emily K Sims, Linda A DiMeglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancerAlex A Adjei, Ann Mauer, Laura Bruzek, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 7, 2014
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanomaPaul Monk, Elaine Lam, Amir Mortazavi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2017
Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?Andrea K Steck, Ping Xu, Susan Geyer, et al.
Leukemia & Lymphoma|February 20, 2016
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665Rebecca DeBoer, Gregory Koval, Flora Mulkey, et al.
Cancer|March 18, 2014
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
Cancer|November 14, 2006
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphomaIvana N M Micallef, Brad S Kahl, Matthew J Maurer, et al.
Diabetes|May 23, 2020
Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention TrialsJay M Sosenko, Jay S Skyler, Kevan C Herold, et al.
Leukemia & Lymphoma|January 20, 2016
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemiaAlison R Walker, Hongyan Wang, Katherine Walsh, et al.
Pageof 12

Showing results (31-40 of 112) with videos related to

Sort By:
Pageof 12
Diabetes Care|July 14, 2018
A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at RiskMaria J Redondo, Susan Geyer, Andrea K Steck, et al.
JCI Insight|August 10, 2018
β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosisCarmella Evans-Molina, Emily K Sims, Linda A DiMeglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancerAlex A Adjei, Ann Mauer, Laura Bruzek, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 7, 2014
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanomaPaul Monk, Elaine Lam, Amir Mortazavi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2017
Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?Andrea K Steck, Ping Xu, Susan Geyer, et al.
Leukemia & Lymphoma|February 20, 2016
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665Rebecca DeBoer, Gregory Koval, Flora Mulkey, et al.
Cancer|March 18, 2014
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
Cancer|November 14, 2006
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphomaIvana N M Micallef, Brad S Kahl, Matthew J Maurer, et al.
Diabetes|May 23, 2020
Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention TrialsJay M Sosenko, Jay S Skyler, Kevan C Herold, et al.
Leukemia & Lymphoma|January 20, 2016
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemiaAlison R Walker, Hongyan Wang, Katherine Walsh, et al.
Pageof 12